Passive immunization against Pseudomonas aeruginosa recombinant PilA in a murine burn wound model.
Pseudomonas aeruginosa type IV pili have an essential role in twitching motility, colonization and biofilm formation. In this study, we investigated the efficacy of intraperitoneal administration of rabbit anti-recombinant PilA (anti-r-PilA) immunoglobulin G (IgG) against P. aeruginosa infection in a mouse burn-wound model. After burn and infection, mortality rate was assessed in all mice, and that of mice passively immunized with rabbit anti-r-PilA IgG was compared to non-immunized mice. Bacterial quantities in the skin and internal organs were measured to determine the level of systemic infection. Results showed that passive immunotherapy with anti-r-PilA IgG protected the burned mice infected with P. aeruginosa strains, PAO1 and the clinical isolate (CI). Anti-r-PilA antibodies enhanced the opsonophagocytosis of these strains. Moreover, the administration of anti-r-PilA IgG was also successful in reducing the bacterial burden in infected mice. The reduction of systemic bacterial spread increased the survival rate of passively immunized mice. Findings of this study revealed an improved survival rate of 62.5%, thus confirming the protective effect of anti-r-PilA IgG.
Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Iran.
Mehdi
M
Mousavi
Department of Microbiology, Tehran University of Medical Sciences, Tehran, Iran.
Bahador
B
Behrouz
Department of Microbiology, Iran University of Medical Sciences, Tehran, Iran.
Gholamreza
G
Irajian
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Mehdi
M
Mahdavi
Department of Microbiology, Iran University of Medical Sciences, Tehran, Iran.
Fatemeh
F
Korpi
Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Iran; Shiraz HIV/AIDS Research Center (SHARC), Shiraz, Iran. Electronic address: motamedifarmohammad@gmail.com.
Mohammad
M
Motamedifar
D000825:Animal Structures / Q000382:microbiology; D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage; D016470:Bacteremia / Q000517:prevention & control*; D058491:Bacterial Load; D002056:Burns / Q000150:complications*; D004195:Disease Models, Animal; D036781:Fimbriae Proteins / Q000037:antagonists & inhibitors / Q000276:immunology*; D007116:Immunization, Passive / Q000379:methods*; D007074:Immunoglobulin G / Q000008:administration & dosage; D007155:Immunologic Factors / Q000008:administration & dosage; D007274:Injections, Intraperitoneal; D051379:Mice; D011552:Pseudomonas Infections / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome; D014946:Wound Infection / Q000150:complications / Q000628:therapy*
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D007155:Immunologic Factors; D011994:Recombinant Proteins; D036781:Fimbriae Proteins
Antibody; Burn; Pseudomonas aeruginosa; Recombinant PilA